endpoint, a San Francisco, CA-based company dedicated to the development of Interactive Response Technology (IVR/IWR) platforms for the life sciences industry, has received a minority equity investment from Chiltern International Limited, a global contract research organization (CRO).
endpoint’s configurable system, PULSE, which allows users to design and deploy clinical trial IRT systems that can be accessed via the phone, web, or mobile device, was launched in January of this year.
Comenting on the deal, Glenn Kerkhof, Chiltern CEO, was quoted as saying: “Chiltern’s decision to invest in endpoint is representative of our commitment to seek collaborations which connect Chiltern and our clients with leading edge solutions as well as our belief in the technology that endpoint has developed.
“Jon Dole and Tom O’Connell are bringing a new level of energy and innovation to Interactive Response Technology services to provide solutions which are meeting clients’ needs for flexibility, efficiency and savings while ensuring the highest possible quality.
“We believe that endpoint has listened – and is responding – to the industry’s needs for IVR/IWR solutions and we look forward to introducing endpoint to our customers as a Chiltern qualified vendor that will meet their needs and exceed their expectations in a manner that mirrors Chiltern’s commitment to the same”.